Answers are grounded in this paper and cite their sources.
To identify serum biomarkers for early risk stratification of severe acute pancreatitis (SAP) using widely targeted metabolomics in an exploratory discovery cohort. Serum samples from 11 healthy controls, 44 patients with mild acute pancreatitis (MAP), and 20 SAP patients were analyzed by UPLC-MS/MS Multivariate statistical analyses (principal component analysis [PCA] and Orthogonal partial least squares discriminant analysis [OPLS-DA]) were applied to compare metabolic profiles. Candidate biomarkers were screened by VIP > 1, p < 0.05, and AUC > 0.9, followed by pathway enrichment and diagnostic performance evaluation. The three groups showed gradient metabolic separation. A total of 353 differentially expressed metabolites were detected between SAP and MAP, with glycerophospholipid metabolism as the most significantly enriched pathway. Among the top 20 metabolites ranked by VIP, five had AUC > 0.9. After excluding three substances prone to exogenous interference, Asp-Leu-Ala-Glu and 3-hydroxytetradecanoic acid were retained as potential endogenous candidate biomarkers for SAP. These metabolites were significantly elevated in SAP compared to MAP, with no significant difference observed between MAP and healthy controls, achieving AUCs of 0.914 (95% CI: 0.835-0.973) and 0.935 (95% CI: 0.849-0.991), respectively. Progression to SAP involves characteristic metabolic reprogramming dominated by glycerophospholipid metabolism. The two identified metabolites are promising candidate biomarkers for early risk stratification of SAP.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: